{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:31:56Z","timestamp":1754159516264,"version":"3.41.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00108-025-01945-x","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T02:48:07Z","timestamp":1751251687000},"page":"810-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T-Zellen bei nicht-malignen Erkrankungen","CAR T cells in non-malignant diseases"],"prefix":"10.1007","volume":"66","author":[{"given":"Fabian","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Mackensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"1945_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","author":"R Kansal","year":"2019","unstructured":"Kansal\u00a0R, Richardson\u00a0N, Neeli\u00a0I, Khawaja\u00a0S, Chamberlain\u00a0D, Ghani\u00a0M, Ghani\u00a0QU, Balazs\u00a0L, Beranova-Giorgianni\u00a0S, Giorgianni\u00a0F et\u00a0al (2019) Sustained B\u00a0cell depletion by CD19-targeted CAR T\u00a0cells is a\u00a0highly effective treatment for murine lupus. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aav1648","journal-title":"Sci Transl Med"},{"key":"1945_CR2","doi-asserted-by":"publisher","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bijlsma\u00a0JWJ, Burmester\u00a0GR, Dougados\u00a0M, Kerschbaumer\u00a0A, McInnes\u00a0IB, Sepriano\u00a0A, van Vollenhoven\u00a0RF, de Wit M et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"1945_CR3","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1093\/rheumatology\/keab827","volume":"61","author":"VR Reddy","year":"2022","unstructured":"Reddy\u00a0VR, Pepper\u00a0RJ, Shah\u00a0K, Cambridge\u00a0G, Henderson\u00a0SR, Klein\u00a0C, Kell\u00a0L, Taylor\u00a0SJ, Isenberg\u00a0DA, Cragg\u00a0MS, Leandro\u00a0MJ (2022) Disparity in peripheral and renal B\u2011cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab? Rheumatology 61:2894\u20132904. https:\/\/doi.org\/10.1093\/rheumatology\/keab827","journal-title":"Rheumatology"},{"key":"1945_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos\u00a0D, Kronke\u00a0G, Volkl\u00a0S, Kretschmann\u00a0S, Aigner\u00a0M, Kharboutli\u00a0S, Boltz\u00a0S, Manger\u00a0B, Mackensen\u00a0A, Schett\u00a0G (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N\u00a0Engl J Med 385:567\u2013569. https:\/\/doi.org\/10.1056\/NEJMc2107725","journal-title":"N Engl J Med"},{"key":"1945_CR5","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen\u00a0A, Muller\u00a0F, Mougiakakos\u00a0D, Boltz\u00a0S, Wilhelm\u00a0A, Aigner\u00a0M, Volkl\u00a0S, Simon\u00a0D, Kleyer\u00a0A, Munoz\u00a0L et\u00a0al (2022) Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus. Nat Med 28:2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"1945_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann\u00a0C, Muller\u00a0F, Distler\u00a0JHW, Gyorfi\u00a0AH, Volkl\u00a0S, Aigner\u00a0M, Kretschmann\u00a0S, Reimann\u00a0H, Harrer\u00a0T, Bayerl\u00a0N et\u00a0al (2023) Treatment of a\u00a0patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T\u00a0cells. Ann Rheum Dis 82:1117\u20131120. https:\/\/doi.org\/10.1136\/ard-2023-223952","journal-title":"Ann Rheum Dis"},{"key":"1945_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F Muller","year":"2023","unstructured":"Muller\u00a0F, Boeltz\u00a0S, Knitza\u00a0J, Aigner\u00a0M, Volkl\u00a0S, Kharboutli\u00a0S, Reimann\u00a0H, Taubmann\u00a0J, Kretschmann\u00a0S, Rosler\u00a0W et\u00a0al (2023) CD19-targeted CAR T\u00a0cells in refractory antisynthetase syndrome. Lancet 401:815\u2013818. https:\/\/doi.org\/10.1016\/S0140-6736(23)00023-5","journal-title":"Lancet"},{"key":"1945_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L, Wilhelm\u00a0A, Bergmann\u00a0C, Volkl\u00a0S, Aigner\u00a0M, Rothe\u00a0T, Minopoulou\u00a0I, Tur\u00a0C et\u00a0al (2024) CD19 CAR T\u2011cell therapy in autoimmune disease\u2014A case series with follow-up. N\u00a0Engl J Med 390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"key":"1945_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang\u00a0W, He\u00a0S, Zhang\u00a0W, Zhang\u00a0H, DeStefano\u00a0VM, Wada\u00a0M, Pinz\u00a0K, Deener\u00a0G, Shah\u00a0D, Hagag\u00a0N et\u00a0al (2024) BCMA-CD19 compound CAR T\u00a0cells for systemic lupus erythematosus: a\u00a0phase\u00a01 open-label clinical trial. Ann Rheum Dis 83:1304. https:\/\/doi.org\/10.1136\/ard-2024-225785","journal-title":"Ann Rheum Dis"},{"key":"1945_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03718-3","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller\u00a0F, Wirsching\u00a0A, Hagen\u00a0M, V\u00f6lkl\u00a0S, Tur\u00a0C, Raimondo\u00a0MG, Taubmann\u00a0J, Bucci\u00a0L, Zhang\u00a0L, Kretschmann\u00a0S et\u00a0al (2025) BCMA-CAR T\u2011cells in a\u00a0patient with relapsing idiopathic inflammatory myositis after CD19-CAR T\u2011cells. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03718-3","journal-title":"Nat Med"},{"key":"1945_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146743","author":"CS Walti","year":"2021","unstructured":"Walti\u00a0CS, Krantz\u00a0EM, Maalouf\u00a0J, Boonyaratanakornkit\u00a0J, Keane-Candib\u00a0J, Joncas-Schronce\u00a0L, Stevens-Ayers\u00a0T, Dasgupta\u00a0S, Taylor\u00a0JJ, Hirayama\u00a0AV et\u00a0al (2021) Antibodies against vaccine-preventable infections after CAR-T\u00a0cell therapy for B\u00a0cell malignancies. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.146743","journal-title":"JCI Insight"},{"key":"1945_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","volume":"57","author":"T Alexander","year":"2022","unstructured":"Alexander\u00a0T, Greco\u00a0R (2022) Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 57:1055\u20131062. https:\/\/doi.org\/10.1038\/s41409-022-01702-w","journal-title":"Bone Marrow Transplant"},{"key":"1945_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.179433","author":"A Wilhelm","year":"2024","unstructured":"Wilhelm\u00a0A, Chambers\u00a0D, M\u00fcller\u00a0F, Bozec\u00a0A, Grieshaber-Bouyer\u00a0R, Winkler\u00a0T, Mougiakakos\u00a0D, Mackensen\u00a0A, Schett\u00a0G, Kr\u00f6nke\u00a0G (2024) Selective CAR T\u00a0cell-mediated B\u00a0cell depletion suppresses IFN signature in SLE. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.179433","journal-title":"JCI Insight"},{"key":"1945_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur\u00a0C, Eckstein\u00a0M, Velden\u00a0J, Rauber\u00a0S, Bergmann\u00a0C, Auth\u00a0J, Bucci\u00a0L, Corte\u00a0G, Hagen\u00a0M, Wirsching\u00a0A et\u00a0al (2025) CD19-CAR T\u2011cell therapy induces deep tissue depletion of B\u00a0cells. Ann Rheum Dis 84:106\u2013114. https:\/\/doi.org\/10.1136\/ard-2024-226142","journal-title":"Ann Rheum Dis"},{"key":"1945_CR15","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/s2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth\u00a0J, M\u00fcller\u00a0F, V\u00f6lkl\u00a0S, Bayerl\u00a0N, Distler\u00a0JHW, Tur\u00a0C, Raimondo\u00a0MG, Chenguiti Fakhouri\u00a0S, Atzinger\u00a0A, Coppers\u00a0B et\u00a0al (2025) CD19-targeting CAR T\u2011cell therapy in patients with diffuse systemic sclerosis: a\u00a0case series. Lancet Rheumatol 7:e83\u2013e93. https:\/\/doi.org\/10.1016\/s2665-9913(24)00282-0","journal-title":"Lancet Rheumatol"},{"key":"1945_CR16","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang\u00a0X, Wu\u00a0X, Tan\u00a0B, Zhu\u00a0L, Zhang\u00a0Y, Lin\u00a0L, Xiao\u00a0Y, Sun\u00a0A, Wan\u00a0X, Liu\u00a0S et\u00a0al (2024) Allogeneic CD19-targeted CAR\u2011T therapy in patients with severe myositis and systemic sclerosis. Cell 187:4890\u20134904.e9. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027","journal-title":"Cell"},{"key":"1945_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1182\/blood-2024-202980","volume":"144","author":"R Li","year":"2024","unstructured":"Li\u00a0R, Zhang\u00a0L, Pan\u00a0H, Li\u00a0W, Ma\u00a0J, Tian\u00a0L, Shen\u00a0Y, Gao\u00a0Z, Zhao\u00a0J, Huang\u00a0K et\u00a0al (2024) CD19 CAR T\u2011cell therapy in refractory autoimmune hemolytic anemia. Blood 144:682\u2013682. https:\/\/doi.org\/10.1182\/blood-2024-202980","journal-title":"Blood"},{"key":"1945_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(24)02504-2","volume":"405","author":"K Trautmann-Grill","year":"2025","unstructured":"Trautmann-Grill\u00a0K, von Bonin\u00a0M, Georgi\u00a0A, Middeke\u00a0JM, B\u00f6ttcher\u00a0M, Meyer\u00a0O, Borie\u00a0D, Bornh\u00e4user\u00a0M, Mikusko\u00a0M, Wolleschak\u00a0D, Mougiakakos\u00a0D (2025) Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T\u00a0cells. Lancet 405:25\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(24)02504-2","journal-title":"Lancet"},{"key":"1945_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin\u00a0C, Tian\u00a0D\u2011S, Zhou\u00a0L\u2011Q, Shang\u00a0K, Huang\u00a0L, Dong\u00a0M\u2011H, You\u00a0Y\u2011F, Xiao\u00a0J, Xiong\u00a0Y, Wang\u00a0W et\u00a0al (2023) Anti-BCMA CAR T\u2011cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase\u00a01\u00a0trial interim results. Signal Transduct Target Ther 8:5. https:\/\/doi.org\/10.1038\/s41392-022-01278-3","journal-title":"Signal Transduct Target Ther"},{"key":"1945_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach\u00a0F, Richter\u00a0J, Pfeffer\u00a0LK, Fehse\u00a0B, Berger\u00a0SC, Reinhardt\u00a0S, Kuhle\u00a0J, Badbaran\u00a0A, Rathje\u00a0K, Gagelmann\u00a0N et\u00a0al (2024) CD19-targeted chimeric antigen receptor T\u00a0cell therapy in two patients with multiple sclerosis. Med 5:550\u2013558.e2. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002","journal-title":"Med"},{"key":"1945_CR21","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia\u00a0A, Hegelmaier\u00a0T, Wolleschak\u00a0D, B\u00f6ttcher\u00a0M, Desel\u00a0C, Borie\u00a0D, Motte\u00a0J, Schett\u00a0G, Schroers\u00a0R, Gold\u00a0R, Mougiakakos\u00a0D (2023) Anti-CD19 CAR T\u00a0cells for refractory myasthenia gravis. Lancet Neurol 22:1104\u20131105. https:\/\/doi.org\/10.1016\/S1474-4422(23)00375-7","journal-title":"Lancet Neurol"},{"key":"1945_CR22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","volume":"16","author":"D-S Tian","year":"2024","unstructured":"Tian\u00a0D\u2011S, Qin\u00a0C, Dong\u00a0M\u2011H, Heming\u00a0M, Zhou\u00a0L\u2011Q, Wang\u00a0W, Cai\u00a0S\u2011B, You\u00a0Y\u2011F, Shang\u00a0K, Xiao\u00a0J et\u00a0al (2024) B\u00a0cell lineage reconstitution underlies CAR-T\u00a0cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Mol Med 16:966\u2013987. https:\/\/doi.org\/10.1038\/s44321-024-00043-z","journal-title":"EMBO Mol Med"},{"key":"1945_CR23","doi-asserted-by":"publisher","first-page":"e2403227121","DOI":"10.1073\/pnas.2403227121","volume":"121","author":"S Faissner","year":"2024","unstructured":"Faissner\u00a0S, Motte\u00a0J, Sgodzai\u00a0M, Geis\u00a0C, Haghikia\u00a0A, Mougiakakos\u00a0D, Borie\u00a0D, Schroers\u00a0R, Gold\u00a0R (2024) Successful use of anti-CD19 CAR T\u00a0cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci U S\u00a0A 121:e2403227121. https:\/\/doi.org\/10.1073\/pnas.2403227121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1945_CR24","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau\u00a0T, Naumann-Bartsch\u00a0N, Aigner\u00a0M, Kharboutli\u00a0S, Kretschmann\u00a0S, Spoerl\u00a0S, Vasova\u00a0I, V\u00f6lkl\u00a0S, Woelfle\u00a0J, Mackensen\u00a0A et\u00a0al (2024) CAR T\u2011cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403:1627\u20131630. https:\/\/doi.org\/10.1016\/S0140-6736(24)00424-0","journal-title":"Lancet"},{"key":"1945_CR25","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1006\/mthe.2002.0611","volume":"5","author":"SG Deeks","year":"2002","unstructured":"Deeks\u00a0SG, Wagner\u00a0B, Anton\u00a0PA, Mitsuyasu\u00a0RT, Scadden\u00a0DT, Huang\u00a0C, Macken\u00a0C, Richman\u00a0DD, Christopherson\u00a0C, June\u00a0CH et\u00a0al (2002) A\u00a0phase\u00a0II randomized study of HIV-specific T\u2011cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:788\u2013797. https:\/\/doi.org\/10.1006\/mthe.2002.0611","journal-title":"Mol Ther"},{"key":"1945_CR26","doi-asserted-by":"publisher","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","volume":"11","author":"K Anthony-Gonda","year":"2019","unstructured":"Anthony-Gonda\u00a0K, Bardhi\u00a0A, Ray\u00a0A, Flerin\u00a0N, Li\u00a0M, Chen\u00a0W, Ochsenbauer\u00a0C, Kappes\u00a0JC, Krueger\u00a0W, Worden\u00a0A et\u00a0al (2019) Multispecific anti-HIV duoCAR-T\u00a0cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a\u00a0humanized mouse model. Sci Transl Med 11:eaav5685. https:\/\/doi.org\/10.1126\/scitranslmed.aav5685","journal-title":"Sci Transl Med"},{"key":"1945_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","volume":"10","author":"Y Mao","year":"2024","unstructured":"Mao\u00a0Y, Liao\u00a0Q, Zhu\u00a0Y, Bi\u00a0M, Zou\u00a0J, Zheng\u00a0N, Zhu\u00a0L, Zhao\u00a0C, Liu\u00a0Q, Liu\u00a0L et\u00a0al (2024) Efficacy and safety of novel multifunctional M10 CAR-T\u00a0cells in HIV-1-infected patients: a\u00a0phase\u00a0I, multicenter, single-arm, open-label study. Cell Discov 10:49. https:\/\/doi.org\/10.1038\/s41421-024-00658-z","journal-title":"Cell Discov"},{"key":"1945_CR28","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1172\/jci120228","volume":"129","author":"K Wisskirchen","year":"2019","unstructured":"Wisskirchen\u00a0K, Kah\u00a0J, Malo\u00a0A, Asen\u00a0T, Volz\u00a0T, Allweiss\u00a0L, Wettengel\u00a0JM, L\u00fctgehetmann\u00a0M, Urban\u00a0S, Bauer\u00a0T et\u00a0al (2019) T\u00a0cell receptor grafting allows virological control of Hepatitis\u00a0B virus infection. J\u00a0Clin Invest 129:2932\u20132945. https:\/\/doi.org\/10.1172\/jci120228","journal-title":"J Clin Invest"},{"key":"1945_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik\u00a0JG, Tomb\u00e1cz\u00a0I, Yadegari\u00a0A, M\u00e9ndez Fern\u00e1ndez\u00a0PO, Shewale\u00a0SV, Li\u00a0L, Kimura\u00a0T, Soliman\u00a0OY, Papp\u00a0TE, Tam\u00a0YK et\u00a0al (2022) CAR T\u00a0cells produced in vivo to treat cardiac injury. Science 375:91\u201396. https:\/\/doi.org\/10.1126\/science.abm0594","journal-title":"Science"},{"key":"1945_CR30","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3385749\/v1","author":"C Amor","year":"2023","unstructured":"Amor\u00a0C, Fern\u00e1ndez-Maestre\u00a0I, Chowdhury\u00a0S, Ho\u00a0YJ, Nadella\u00a0S, Graham\u00a0C, Carrasco\u00a0SE, Nnuji-John\u00a0E, Feucht\u00a0J, Hinterleitner\u00a0C et\u00a0al (2023) Prophylactic and long-lasting efficacy of senolytic CAR T\u00a0cells against age-related metabolic dysfunction. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-3385749\/v1","journal-title":"Res Sq"},{"key":"1945_CR31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ajt.14175","volume":"17","author":"F Noyan","year":"2017","unstructured":"Noyan\u00a0F, Zimmermann\u00a0K, Hardtke-Wolenski\u00a0M, Knoefel\u00a0A, Schulde\u00a0E, Geffers\u00a0R, Hust\u00a0M, Huehn\u00a0J, Galla\u00a0M, Morgan\u00a0M et\u00a0al (2017) Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am J Transplant 17:917\u2013930. https:\/\/doi.org\/10.1111\/ajt.14175","journal-title":"Am J Transplant"},{"key":"1945_CR32","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","volume":"103","author":"M Tenspolde","year":"2019","unstructured":"Tenspolde\u00a0M, Zimmermann\u00a0K, Weber\u00a0LC, Hapke\u00a0M, Lieber\u00a0M, Dywicki\u00a0J, Frenzel\u00a0A, Hust\u00a0M, Galla\u00a0M, Buitrago-Molina\u00a0LE et\u00a0al (2019) Regulatory T\u00a0cells engineered with a\u00a0novel insulin-specific chimeric antigen receptor as a\u00a0candidate immunotherapy for type\u00a01 diabetes. J\u00a0Autoimmun 103:102289. https:\/\/doi.org\/10.1016\/j.jaut.2019.05.017","journal-title":"J Autoimmun"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01945-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:19:30Z","timestamp":1753445970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1945"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01945-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"17 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0M\u00fcller erhielt Forschungsmittel von AstraZeneca, Kite\/Gilead und BMS, hat beraten f\u00fcr AbbVie, ArgoBio, AstraZeneca, BMS, BioNTech, Crispr Therapeutics, Janssen, Kite, Miltenyi Biomedicine und Novartis und erhielt Honoraria von AbbVie, ArgoBio, AstraZeneca, BMS, Crispr Therapeutics, Janssen, Kite, Kyverna, Miltenyi Biomedicine, Novartis,und Sobi.  M.\u00a0Hagen erhielt Honoraria von BMS, Lilly, Alfasigma und UCB und Reiseunterst\u00fctzung von Kyverna.  G.\u00a0Schett erhielt Honoraria von BMS, Cabaletta, Janssen, Kyverna, Miltenyi, und Novartis und ist Anteilseigener von Kyverna.  A.\u00a0Mackensen erhielt Forschungsmittel von Miltenyi Biomedicine, Kyverna und Century Therapeutics, hat beraten f\u00fcr BMS\/Celgene, KITE\/Gilead, Novartis, BioNTech, Miltenyi Biomedicine und Century Therapeutics, erhielt Honoraria von BMS\/Celgene, KITE\/Gilead, Novartis, Miltenyi Biomedicine und Reiseunterst\u00fctzung von AbbVie und Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}